Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial

Aims/hypothesis Hyperbaric oxygen (HBO) therapy may improve hyperglycaemia in humans with type 2 diabetes, but underlying mechanisms are unclear. Our objective was to examine the glucometabolic effects of HBO on whole-body glucose disposal in humans with type 2 diabetes. Methods In a randomised plac...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2023-01, Vol.66 (1), p.57-69
Main Authors: Sarabhai, Theresia, Mastrototaro, Lucia, Kahl, Sabine, Bönhof, Gidon J., Jonuscheit, Marc, Bobrov, Pavel, Katsuyama, Hisayuki, Guthoff, Rainer, Wolkersdorfer, Martin, Herder, Christian, Meuth, Sven G., Dreyer, Sven, Roden, Michael
Format: Article
Language:English
Subjects:
Adipose tissue
Adolescent
Adult
Aged
AKT protein
Blood glucose
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - therapy
Endoplasmic reticulum
Energy metabolism
Glucose
Human Physiology
Humans
Hyperbaric oxygen
Hyperbaric Oxygenation
Hyperglycemia
Insulin
Insulin receptor substrate 1
Insulin Resistance
Internal Medicine
Liver
Magnetic resonance spectroscopy
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Mitochondria
Musculoskeletal system
Oxygen
Oxygen therapy
Phosphorylation
Placebos
Reactive oxygen species
Respiration
Serine
Skeletal muscle
Threonine
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis Hyperbaric oxygen (HBO) therapy may improve hyperglycaemia in humans with type 2 diabetes, but underlying mechanisms are unclear. Our objective was to examine the glucometabolic effects of HBO on whole-body glucose disposal in humans with type 2 diabetes. Methods In a randomised placebo-controlled crossover trial located at the German Diabetes Center, 12 male individuals with type 2 diabetes (age 18–75 years, BMI
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-022-05797-0